RCC-EU

Calcipotriol
0.05 mg/g cream

7215189

1.3.1.1 Summary of Product Characteristics

NL/H/0761/001/DC

Compiler(s): IJ.M. Merkx
Document status: final
Date: 16 April 2007
Document Code: 7215189-1311-967_155d-00
Number of pages: 8

Property of Sandoz GmbH
Confidential
May not be used, divulged or otherwise disclosed without the consent of Sandoz GmbH
1. **NAME OF THE MEDICINAL PRODUCT**

[nationally completed name]

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

One gram of cream contains 0.05 mg (is equal to 50 micrograms) of calcipotriol.

Excipient: Cetostearyl alcohol 60 mg/g
For a full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

Cream
White cream.

4. **CLINICAL PARTICULARS**

4.1 **Therapeutic indications**

Calcipotriol cream is indicated for the topical treatment of mild to moderately severe psoriasis (psoriasis vulgaris).

4.2 **Posology and method of administration**

*Adults:*

As monotherapy
The calcipotriol cream should be applied to the affected skin on limbs or trunk once or twice daily. At the beginning of treatment, twice daily (morning and evening) application is recommended. For maintenance therapy, the frequency of application may be decreased to once daily, depending on the response.

Cream has to be applied as a thin layer to affected skin with gentle rubbing to cover the affected area until most of the cream disappears.

The maximum amount of cream applied should not exceed 100 grams per week. If it is used together with ointment or solution containing calcipotriol, the total weekly dose of calcipotriol should not exceed 5 mg (for example 30 ml of scalp solution plus 60 g of cream or ointment).
The duration of therapy depends on the clinical appearance. A pronounced therapeutic effect is generally seen after a maximum of 4-8 weeks. Therapy can be repeated.

**As combination therapy**

Once daily application of calcipotriol cream in combination with topical corticosteroids (e.g. administration of calcipotriol cream in the morning and steroid in the evening) is effective and well tolerated.

**Renal/hepatic impairment**

Patients with known severe renal or liver impairment should not be treated with calcipotriol.

**Children and adolescents (< 18 years):**

There is limited experience with the use of calcipotriol cream in children and adolescents. The efficacy and long-term safety of above mentioned dosage (under adults) has not been established in children and adolescents. Therefore its use in this population cannot be recommended.

### 4.3 Contraindications

- Hypersensitivity to the active substance or to any of the excipients
- Known disorders of calcium metabolism
- Hypercalcaemia

### 4.4 Special warnings and precautions for use

Calcipotriol cream should not be used on the face. Patients should be advised to wash their hands after applying the cream in order to prevent the inadvertent transfer to other areas, especially the face.

The efficacy and long-term safety of calcipotriol cream in children and adolescents has not been established. Therefore its use in this population cannot be recommended.

Hypercalcaemia does not occur with the usual dosage (up to 100 g of cream a week). Excessive use (50-100 g of cream per day) may cause elevations in serum calcium levels which reverse rapidly on discontinuation of treatment. Studies on adults over a period of one year have not yielded any evidence of a risk of hypercalcaemia. However, the serum calcium level should be monitored on long-term use with application to extensive areas of skin.

In view of a possible effect on calcium metabolism, patients should be advised to use no more than the recommended dose (see section 4.2.) and the addition of penetration-promoting substances (such as salicylic acid) to the cream is not permitted. Occlusion is undesirable for the same reason.
The clinical symptoms of hypercalcaemia may resemble those of cholecalciferol overdose, i.e. the hypercalcaemia syndrome or calcium intoxication (see section 4.9), depending on the intensity and duration of the hypercalcaemia. Persistent hypercalcaemia may result in ectopic deposits of calcium in the blood vessel walls, joint capsules, gastric mucosa, cornea and renal parenchyma.

There are data indicating that the combination of calcipotriol with UV light may cause dark areas of hyperpigmentation; these are reversible. If treatment with calcipotriol cream is started during a course of UV-B therapy, photosensitive eczema may occur.

Patients with known renal or liver impairment should not be treated with this medicinal product due to limited experience.

This medicinal product contains cetostearyl alcohol. It may cause local skin reactions (e.g. contact dermatitis).

4.5 Interaction with other medicinal products and other forms of interaction

Although studies to-date have shown that the combination of calcipotriol cream with UV-A therapy, ciclosporin or acitretin is effective and well-tolerated, there is not enough data that the combination is more effective or that the dosage of the other medicinal products can be reduced.

The cream will not increase the overall effectiveness of UV-B treatment. However, it has a light-saving effect when used in combination with UV-B in adults and response is achieved at a lower dose of UV-B. Calcipotriol cream should be applied at least 2 hours before UV-B therapy. Combination of calcipotriol with UV-B light may cause dark areas of hyperpigmentation (see section 4.4.). Cream should not be initiated where patients may already be receiving an erythemogenic or sub-erythemogenic dose of UV-B.

Concomitant administration of calcipotriol and salicylic acid externals may cause an inactivation of calcipotriol.

There is no experience of concomitant therapy with other antipsoriatic products applied to the same area of skin at the same time.

4.6 Pregnancy and lactation

Pregnancy:
For calcipotriol no data on pregnant patients are available. A limited absorption is expected after local application of calcipotriol cream at small areas. If used as indicated no disturbance of the calcium homeostasis is to be expected. Animal studies do not indicate direct or indirect
harmful effects with respect to reproductive toxicity. As a precautionary measure it is preferable to avoid the use of calcipotriol in pregnancy.

Lactation:
It is unknown whether calcipotriol is excreted in human breast milk. The excretion of calcipotriol in milk has not been studied in animals. As a precautionary measure it is preferable to avoid the use of calcipotriol in lactation.

4.7 Effects on ability to drive and use machines

In view of the nature of the product and the indications for its use, no effect on the ability to drive and use machines is to be expected.

4.8 Undesirable effects

Based on the clinical data undesirable effects occurred in approximately 25% of the patients.

The most frequently reported undesirable effects are various transient skin reactions and in particular application site reactions, which seldom requires discontinuation of treatment.

Pruritus, skin irritation, burning and stinging sensation, dry skin, erythema and rash are common.

The undesirable effects are listed by MedDra SOC and the individual undesirable effects are listed starting with the most frequently reported.

Skin and subcutaneous disorders

<table>
<thead>
<tr>
<th>Category</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common (&gt;1/100 and &lt;1/10)</td>
<td>Pruritus, skin burning sensation, skin stinging sensation, skin irritation, skin dry, erythema, rash*</td>
</tr>
<tr>
<td>Uncommon (&gt;1/1,000 and &lt;1/100)</td>
<td>Eczema, contact dermatitis, aggravated, psoriasis</td>
</tr>
</tbody>
</table>

* various types of rash reaction such as scaly, erythematous, maculo-papular and pustular have been reported.

Metabolism and nutrition disorders

<table>
<thead>
<tr>
<th>Category</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very rare (&lt;1/10,000)</td>
<td>Hypercalcaemia, hypercalciuria</td>
</tr>
</tbody>
</table>

The following undesirable effects have been reported for calcipotriol cream, ointment and scalp solution during post-marketing experience: transient changes in skin pigmentation, transient photosensitivity reaction and hypersensitivity reaction including urticaria, angioedema, periorbital or facial oedema (very rarely). Perioral dermatitis may occur rarely.
Based on post-marketing data the total ‘reporting rate’ of undesirable effects is very rare being approximately 1:10,000 treatment courses.

4.9 Overdose

The possible occurrence of hypercalcaemia at the recommended dosage cannot be excluded. Excessive use (more than 50-100 grams per day) may result in an elevated serum calcium level, which disappears rapidly after cessation of treatment, and hypercalcaemia has been reported at lower doses in patients with generalised pustular or erythrodermic exfoliative psoriasis. The clinical signs of hypercalcaemia include anorexia, nausea, vomiting, constipation, hypotonia, depression, lethargy and coma.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Other antipsoriatics for topical use, ATC code: D05AX02

Calcipotriol is a vitamin D derivative. In vitro data show that calcipotriol induces differentiation and suppresses proliferation of keratinocytes. The effect of calcipotriol in psoriasis is ascribed mainly to this.

An effect, first of all on the desquamation, then on the infiltration and finally on the erythema, is seen after two to four weeks of treatment. The maximum effect is usually achieved after six weeks.

5.2 Pharmacokinetic properties

Data from a single study containing 5 evaluable patients with psoriasis treated with 0.3 – 1.7 g of a 50 micrograms/g tritium labelled calcipotriol ointment suggested that less than 1% of the dose was absorbed. However, total recovery of the tritium label over a 96 hour period ranged from 6.7 to 32.6%, figures maximised by uncorrected chemiluminescence. There were no data on tissue distribution from the lungs.

5.3 Preclinical safety data

Studies in rats have shown that the effect of calcipotriol on calcium metabolism is approximately 100 times less than that of active vitamin D3 (1,25(OH)2D3, calcitriol). There are no other preclinical data considered relevant to clinical safety beyond data included in other sections of the SPC.
6. **PHARMACEUTICAL PARTICULARS**

6.1 **List of excipients**

- Disodium edetate
- Disodium phosphate dihydrate
- Sodium dihydrogen phosphate dihydrate
- Chloroallylmethenamine chloride
- Glycerol
- Macrogol cetostearyl ether
- Cetostearyl alcohol
- Paraffin, light liquid
- Paraffin, white soft
- Water, purified

6.2 **Incompatibilities**

Not applicable.

6.3 **Shelf life**

2 years

After first opening: 3 months

6.4 **Special precautions for storage**

Do not store above 25°C. Do not freeze.

6.5 **Nature and contents of container**

Membrane closed aluminium tube with polyethylene neck and screw cap.

Pack sizes: 30, 120 gram.
Not all pack sizes may be marketed.

6.6 **Special precautions for disposal and other handling**
No special requirements.

7. MARKETING AUTHORISATION HOLDER

8. MARKETING AUTHORISATION NUMBER(S)

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

10. DATE OF REVISION OF THE TEXT